Form 6K Opthea Ltd For: 12 November
- Investing.com
Metrics to compare | CYVNY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYVNYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −2.0x | −0.4x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.4x | 3.7x | 2.6x | |
Price / LTM Sales | 12,436.2x | 11.1x | 3.0x | |
Upside (Analyst Target) | - | 106.0% | 51.3% | |
Fair Value Upside | Unlock | 8.5% | 7.8% | Unlock |
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.